Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

Translated title of the contribution: Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept

J. H. Jung, J. H. Kim, Gwan Gyu Song

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

Original languageGerman
Pages (from-to)372-374
Number of pages3
JournalZeitschrift fur Rheumatologie
Volume76
Issue number4
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Pulmonary Sarcoidosis
Sarcoidosis
Tumor Necrosis Factor-alpha
Ankylosing Spondylitis
Therapeutics
Etanercept
Adalimumab

Keywords

  • Adalimumab
  • Etanercept
  • Paradoxical response
  • Pulmonary sarcoidosis
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Rheumatology

Cite this

Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept. / Jung, J. H.; Kim, J. H.; Song, Gwan Gyu.

In: Zeitschrift fur Rheumatologie, Vol. 76, No. 4, 01.05.2017, p. 372-374.

Research output: Contribution to journalArticle

@article{123c5839d4ad4fcab2f7a089dd2cf253,
title = "Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept",
abstract = "Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.",
keywords = "Adalimumab, Etanercept, Paradoxical response, Pulmonary sarcoidosis, Tumor necrosis factor-α",
author = "Jung, {J. H.} and Kim, {J. H.} and Song, {Gwan Gyu}",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s00393-016-0262-4",
language = "German",
volume = "76",
pages = "372--374",
journal = "Zeitschrift fur Rheumatologie",
issn = "0340-1855",
publisher = "D. Steinkopff-Verlag",
number = "4",

}

TY - JOUR

T1 - Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

AU - Jung, J. H.

AU - Kim, J. H.

AU - Song, Gwan Gyu

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

AB - Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

KW - Adalimumab

KW - Etanercept

KW - Paradoxical response

KW - Pulmonary sarcoidosis

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=85010809781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010809781&partnerID=8YFLogxK

U2 - 10.1007/s00393-016-0262-4

DO - 10.1007/s00393-016-0262-4

M3 - Article

VL - 76

SP - 372

EP - 374

JO - Zeitschrift fur Rheumatologie

JF - Zeitschrift fur Rheumatologie

SN - 0340-1855

IS - 4

ER -